Service Rendered Directly To Third Parties was Jrsis Health Care’s largest revenue line in fiscal 2023, bringing in $1.39M of $3.46M (40%).
| Related Party, Type | FY 2023 |
|---|---|
| Service Rendered Directly To Third Parties | $1.39M |
| Service Rendered To Related Parties | $959.26K |
| Goods Sold To Related Parties | $773.50K |
| Goods Sold Directly To Third Parties | $336.61K |
| Total | $3.46M |
Jrsis Health Care brought in $3.46M from its four revenue lines in fiscal 2023, the year ended December 31, 2023. Service Rendered Directly To Third Parties was the largest at $1.39M (40.2%), ahead of Service Rendered To Related Parties at $959.26K (27.7%) and Goods Sold To Related Parties at $773.50K (22.3%). The remaining revenue line, Goods Sold Directly To Third Parties, brought in $336.61K.
Patient Services was Jrsis Health Care’s largest revenue line in fiscal 2021, bringing in $17.51M of $26.55M (66%).
| Health Care Organization Revenues | FY 2014 | FY 2017 | FY 2018 | FY 2020 | FY 2021 |
|---|---|---|---|---|---|
| Patient Services | — | $12.62M | $17.51M | ||
| Medical Consulting | $8.72M | — | — | ||
| Western Pharmaceuticals | $8.61M | — | — | ||
| Pharmaceuticals | — | $7.24M | $9.04M | ||
| Medical Treatment | $8.11M | — | — | ||
| Western Medicine | — | — | — | ||
| Chinese Medicine | $1.75M | — | — | ||
| Herbal Medicine | $816.31K | — | — | ||
| Others | $392.77K | — | — | ||
| Total | $28.40M | $19.86M | $26.55M |
Jrsis Health Care brought in $26.55M from its two revenue lines in fiscal 2021, the year ended December 31, 2021. That is less than the $44.39M it reports by breakdown, so these revenue lines do not cover all of its revenue. Patient Services was the largest at $17.51M (66.0%), ahead of Pharmaceuticals at $9.04M (34.0%).
Compared with fiscal 2020, Patient Services grew 38.8% to $17.51M and Pharmaceuticals grew 24.9% to $9.04M.
Jrsis Health Care began breaking out Patient Services in fiscal 2020 and Pharmaceuticals in fiscal 2020. Jrsis Health Care stopped reporting Medical Consulting ($8.72M in fiscal 2018), Western Pharmaceuticals ($8.61M in fiscal 2018), Medical Treatment ($8.11M in fiscal 2018) and three others as separate revenue lines.
Medical Treatment was Jrsis Health Care’s largest revenue line in fiscal 2021, bringing in $17.51M of $44.39M (39%).
| Breakdown | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 |
|---|---|---|---|---|---|
| Medical Treatment | — | — | $12.29M | $17.51M | |
| Patient Services | Medical Treatment | — | $9.94M | — | — | |
| Medical Consulting | — | — | $12.62M | $14.13M | |
| Patient Services | Medical Consulting | — | $9.64M | — | — | |
| Product | $8.61M | — | — | — | |
| Service | $8.72M | — | — | — | |
| Western Pharmaceuticals | — | — | $7.24M | $9.04M | |
| Western Medicine | — | $8.33M | — | — | |
| Herbal Medicine | — | — | $1.30M | $1.51M | |
| Medicine | Herbal Medicine | — | $1.05M | — | — | |
| Others | — | $1.11M | $1.40M | $1.25M | |
| Chinese Medicine | — | — | $864.53K | $956.50K | |
| Medicine | Chinese Medicine | — | $1.40M | — | — | |
| Total | $17.33M | $31.46M | $35.71M | $44.39M |
Jrsis Health Care brought in $44.39M from its six revenue lines in fiscal 2021, the year ended December 31, 2021. That was up 24.3% from $35.71M in fiscal 2020. Medical Treatment was the largest at $17.51M (39.4%), ahead of Medical Consulting at $14.13M (31.8%) and Western Pharmaceuticals at $9.04M (20.4%). The other three revenue lines brought in $3.71M combined.
Compared with fiscal 2020, Medical Treatment grew fastest, up 42.5% to $17.51M, while Others fell the most, down 10.8% to $1.25M.
Jrsis Health Care began breaking out Medical Treatment in fiscal 2020, Medical Consulting in fiscal 2020, Western Pharmaceuticals in fiscal 2020 and Herbal Medicine in fiscal 2020. Jrsis Health Care stopped reporting Patient Services | Medical Treatment ($9.94M in fiscal 2019), Patient Services | Medical Consulting ($9.64M in fiscal 2019), Service ($8.72M in fiscal 2018) and four others as separate revenue lines.
Jrsis Health Care (JRSS) reports its revenue by related party, type, by health care organization revenues and by breakdown. In fiscal 2023, Service Rendered Directly To Third Parties was its largest revenue line, bringing in $1.39M (40.2% of the total), followed by Service Rendered To Related Parties at $959.26K (27.7%).
Service Rendered Directly To Third Parties was Jrsis Health Care's largest revenue line in fiscal 2023, bringing in $1.39M, or 40.2% of the $3.46M total across its four revenue lines.
Patient Services grew faster than Pharmaceuticals in fiscal 2021, up 38.8% from $12.62M to $17.51M. Pharmaceuticals grew 24.9% to $9.04M.
Every figure comes from Jrsis Health Care's annual financial filings, as reported. Each line keeps the name Jrsis Health Care gives it, and years follow its fiscal calendar.
Jrsis Health Care's revenue by related party, type goes back to fiscal 2023, with figures through fiscal 2023. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.